<DOC>
	<DOCNO>NCT01862978</DOCNO>
	<brief_summary>The goal study show efficacy safety heparin nadroparin acute phase ischemic stroke . Therapeutic agent administer interval 4.5 2 hour onset clinical sign . Overall administration anticoagulant agent test 72 hour . Randomized patient divide three group . The first group patient receive heparin intravenously begin 2500 UI bolus intravenously , follow intravenous pump 1000 UI / h ( 18-20 IU / kg / hr ) reach 2-2.5 time baseline aPTT . After 24 hour , patient receive group Nadroparin subcutaneously therapeutic dose . Second group patient administer subcutaneously Nadroparin therapeutic dose recommend . The third group patient receive placebo intravenously 24 hour receive nadroparin subcutaneously therapeutic dose . All patient receive 24 hour start treatment 100 mg aspirin per orally . For initiation treatment assess : - Modified Rankin Scale , National Institutes Health Stroke Scale , inclusion , exclusion criterion - Sign informed consent patient randomization - Laboratory parameter : glucose , creatinine , GGT , K , Na , Cl , blood count , basic coagulation - Women childbearing age ( pregnancy test ) - History , clinical presentation , medical history , basic internal review status ( blood pressure , pulse , body temperature , etc. ) . - Initial CT examination brain - EKG - USG section extracranial carotid vertebral artery - special hematology factor If patient meet necessary criterion , may give test substance . During first 24 hour monitor regular interval vital function . After 24 hour , patient receive subcutaneous Nadroparin therapeutic dose also 100 mg aspirin per orally . In interval 24 30 hour start treatment patient make : - Control CT brain - EKG - Basic coagulation - Reduction stop treatment newly identify haemorrhage severe extensive focal cerebral ischemia CT scan - special hematology factor 72 hour , 7 , 30 90 day start treatment , patient 's clinical evaluation use Modified Rankin Scale , National Institutes Health Stroke Scale Barthel Index . Safety endpoint : mortality , adverse side effect , bleed</brief_summary>
	<brief_title>Safety Efficacy Heparin Nadroparin Acute Phase Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>ischemic stroke female male gender mRS ( modify Rankin Scale ) 01 ( min one month event ) NIHSS ≥ 6 ≤ 25 Age : 1880 year initiation therapy interval 4.5 24 hour onset symptom ischemic stroke focal neurological deficit least 30 min , significantly obviously disappear treatment patient participate voluntarily sign informed consent . Informed consent obtain patient , guardian close relative patient unable sign , able understand mean participate study , may give informed consent eyewitness willingness ability comply protocol intracranial hemorrhage confirm CT scan CT image heavy extensive focal cerebral ischemia lacunar syndrome epileptic seizure begin ischemic stroke previous plan treatment intravenous , intraarterial thrombolysis , mechanical recanalization ultrasound assist thrombolysis stroke , myocardial infarction , head trauma last 3 month tromboctov count 100 000/mm ³ therapeutically uncontrolled blood pressure : systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg therapeutically uncontrolled blood glucose ˂ 2.77 &gt; 22.15 mmol / l Known bleeding diathesis , coagulopathies , severe hepatopathy , severe nephropathy patient receive oral anticoagulant current previous lifethreatening bleed major surgery le 2 week ago know malignancy active TB pregnancy allergy Heparin Fraxiparine know alcohol abuse / drug active participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Heparin</keyword>
	<keyword>Nadroparin</keyword>
</DOC>